Key result
Incretin therapies cut CV death or HF events ~24% in HFpEF/HFmrEF, independent of diabetes.
Why the study?
Whether the cardiovascular benefits of incretin-based therapies in HFpEF/HFmrEF differ by diabetes status across the broader literature remained unclear.
Do incretin-based therapies (GLP-1RAs and tirzepatide) reduce cardiovascular outcomes in patients with HFpEF/HFmrEF independent of diabetes status?
Meta-Analysis
Do incretin-based therapies (GLP-1RAs and tirzepatide) reduce cardiovascular outcomes in patients with HFpEF/HFmrEF independent of diabetes status?
Effect estimate: HR 0.76 (95% CI 0.65-0.87)
Incretin-based therapies significantly reduce heart failure hospitalizations and cardiovascular events in patients with HFpEF/HFmrEF, with comparable benefits regardless of type 2 diabetes status.
Supports consideration of incretin-based therapies in HFpEF/HFmrEF regardless of diabetes; extends RCT meta-analysis evidence to this population.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Shokravi et al. (2026) conducted a meta-analysis in Heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF). Incretin-based therapies (GLP-1RAs and tirzepatide) was evaluated on Composite of CV death or HF hospitalization/events (HR 0.76, 95% CI 0.65-0.87). Incretin-based therapies significantly reduced the composite of CV death or HF hospitalization/events in patients with HFpEF/HFmrEF (HR 0.76; 95% CI 0.65-0.87), independent of diabetes status.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: